Antiplatelet activity of the long-acting thromboxane receptor antagonist BMS 180,291 in monkeys

This publication has 10 references indexed in Scilit:

• Thromboxane receptor antagonist BMS-180291: A new pre-clinical lead
  Bioorganic & Medicinal Chemistry Letters, 1992
• Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT).
  Circulation, 1991
• Thromboxane A2 receptor antagonists
  Medicinal Research Reviews, 1991
• The thromboxane receptor antagonist SQ 30,741 reduces myocardial infarct size in monkeys when given during reperfusion at a threshold dose for improving reflow during thrombolysis
  Journal of the American College of Cardiology, 1990
• Role of protein kinase C in U46619-induced platelet shape change, aggregation and secretion
  Thrombosis Research, 1989
• The Effect of the Thromboxane A2/Prostaglandin Endoperoxide Receptor Antagonist SQ 30,741 on Myocardial Infarct Size and Blood Flow During Myocardial Ischemia and Reperfusion
  Journal of Cardiovascular Pharmacology, 1988
• Electrically induced arterial thrombosis model in the conscious rat
  Thrombosis Research, 1987
• Inhibition of cyclic flow variations in stenosed canine coronary arteries by thromboxane A2/prostaglandin H2 receptor antagonists.
  Circulation Research, 1986
• Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo.
  Journal of Clinical Investigation, 1986
• Thromboxane A2 and the endoperoxides mediate canine platelet activation
  Thrombosis Research, 1981